GSK Profit Beats Estimates on HIV, Cancer Medicines
GSK Plc’s profit was higher than analysts expected in the first quarter, helped by the drugmaker’s specialty medicines for HIV, cancer and immune diseases.
By Ashleigh Furlong, Naomi Kresge · Bloomberg Markets
GSK Plc’s profit was higher than analysts expected in the first quarter, helped by the drugmaker’s specialty medicines for HIV, cancer and immune diseases.